Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Can-Fite Biopharma Ltd ADR
(NY:
CANF
)
2.090
+0.060 (+2.96%)
Official Closing Price
Updated: 8:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Can-Fite Biopharma Ltd ADR
< Previous
1
2
3
4
5
6
Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 25, 2024
Via
Benzinga
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
April 25, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
April 15, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can Fite Biofarma: Q4 Earnings Insights
March 28, 2024
Via
Benzinga
Recap: Can Fite Biofarma Q3 Earnings
November 30, 2023
Via
Benzinga
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
April 03, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
CANF Stock Earnings: Can Fite Biofarma Beats EPS, Beats Revenue for Q4 2023
March 28, 2024
CANF stock results show that Can Fite Biofarma beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Can-Fite Reports 2023 Financial Results and Clinical Update
March 28, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
March 11, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
February 28, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
January 30, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
January 29, 2024
From
Can-Fite BioPharma Ltd.
Via
Business Wire
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
December 20, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
December 18, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
December 04, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
November 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today?
November 21, 2023
Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of
Via
Benzinga
Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
November 21, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
November 01, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
October 30, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
October 26, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
October 24, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
Via
Benzinga
Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
October 09, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
September 27, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
September 07, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
August 31, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
August 24, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
August 18, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
July 17, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
Can-Fite to Present at the Emerging Growth Conference on July 13, 2023
July 07, 2023
From
Can-Fite BioPharma Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.